- Lineage to Present at 2024 BIO International Convention
- Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
- Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
- Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
- Lineage Announces Changes to Board of Directors
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
More ▼
Key statistics
On Saturday, Lineage Cell Therapeutics Inc (LCTX:ASQ) closed at 0.9194, 9.27% above its 52-week low of 0.8414, set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.93 |
---|---|
High | 0.94 |
Low | 0.91 |
Bid | 0.901 |
Offer | 0.9499 |
Previous close | 0.9291 |
Average volume | 808.43k |
---|---|
Shares outstanding | 188.82m |
Free float | 188.00m |
P/E (TTM) | -- |
Market cap | 173.60m USD |
EPS (TTM) | -0.1344 USD |
Data delayed at least 15 minutes, as of Jun 15 2024.
More ▼